![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, May 21, 2024 3:53:17 PM
The canine osteoarthritis study was published 2 months ago and BIEL likely had data from the results long before it was published.
Plenty of time to present the Study's impressive results to potential partners willing to invest in Vagus Nerve research. I don't see BIEL spending money on new patents unless there is a high probability of a near term benefit.
Patent applications are dated so BIEL's May 2024 application would have priority over any similar applications submitted at a later date.
If Clinicals are needed the duration of the Dog Study data collection, with just 14 days of therapy, was quite short. Since BIEL is now a know entity at the FDA, Cleared for 5 indications, the days of year long Clearance times are over. The Post-surgical Pain Clearance took 4 and a half months from submission to decision.
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM